ArticleHeart (British Cardiac Society)2018
Ferumoxytol-enhanced magnetic resonance imaging in acute myocarditis.
Article in Heart (British Cardiac Society), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02319278 (DEtection of Cellular Inflammation With FERumoxytol in the HEART), which is not on this map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
DEtection of Cellular Inflammation With FERumoxytol in the HEART
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis.Frontiers in medicine · 2022Pooled it
- Cardiovascular magnetic resonance native TJournal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2020Pooled it
- Myocardial and Systemic Inflammation in Acute Stress-Induced (Takotsubo) Cardiomyopathy.Circulation · 2019 · on this mapTrial
- Nanomedicine in Cardiovascular Inflammation: Novel Diagnostic and Therapeutic Strategies.Journal of personalized medicine · 2026Review
- Mapping the immune environment: spatiotemporal dynamics in cardiovascular events.Frontiers in immunology · 2026Review
- Magnetic Resonance Imaging in the Evaluation of the Stress System in Acute and Chronic Cardiac Disease.Diagnostics (Basel, Switzerland) · 2025Review
- Unveiling the next generation of MRI contrast agents: current insights and perspectives on ferumoxytol-enhanced MRI.National science review · 2024Review
- Recent trends in preparation and biomedical applications of iron oxide nanoparticles.Journal of nanobiotechnology · 2024Review
- Magnetic resonance imaging contrast-enhancement with superparamagnetic iron oxide nanoparticles amplifies macrophage foam cell apoptosis in human and murine atherosclerosis.Cardiovascular research · 2023Article
- Polyelectrolyte Coating of Ferumoxytol Differentially Impacts the Labeling of Inflammatory and Steady-State Dendritic Cell Subtypes.Biomedicines · 2022Article
- Myocardial inflammation and energetics by cardiac MRI: a review of emerging techniques.BMC medical imaging · 2021Review
- USPIOs as targeted contrast agents in cardiovascular magnetic resonance imaging.Current cardiovascular imaging reports · 2021Article
- Substrate for the Myocardial Inflammation-Heart Failure Hypothesis Identified Using Novel USPIO Methodology.JACC. Cardiovascular imaging · 2021Article
- USPIO-Enhanced CMR of Myocardial Inflammation: What Are We Imaging?JACC. Cardiovascular imaging · 2021Article
- Cardiovascular magnetic resonance imaging for inflammatory heart diseases.Cardiovascular diagnosis and therapy · 2020Review
- Ferumoxytol-enhanced cardiovascular magnetic resonance detection of early stage acute myocarditis.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2019Article
- Cardiac MRI Evaluation of Myocarditis.Current treatment options in cardiovascular medicine · 2019Review
- Molecular Imaging of the Heart.Comprehensive Physiology · 2019Review
Corrections and comments
- Commented on by
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
Abstract
objectivesUltrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced MRI can detect tissue-resident macrophage activity and identify cellular inflammation within tissues. We hypothesised that USPIO-enhanced MRI would provide a non-invasive imaging technique that would improve the diagnosis and management of patients with acute myocarditis.
methodsTen volunteers and 14 patients with suspected acute myocarditis underwent T2, T2* and late gadolinium enhancement (LGE) 3T MRI, with further T2* imaging at 24 hours after USPIO (ferumoxytol, 4 mg/kg) infusion, at baseline and 3 months. Myocardial oedema and USPIO enhancement were determined within areas of LGE as well as throughout the myocardium.
resultsMyocarditis was confirmed in nine of the 14 suspected cases of myocarditis. There was greater myocardial oedema in regions of LGE in patients with myocarditis when compared with healthy volunteer myocardium (T2 value, 57.1±5.3 vs 46.7±1.6 ms, p<0.0001). There was no demonstrable difference in USPIO enhancement between patients and volunteers even within regions displaying LGE (change in R2*, 35.0±15.0 vs 37.2±9.6 s
conclusionIn patients with acute myocarditis, USPIO-enhanced MRI does not provide additional clinically relevant information to LGE and T2 mapping MRI. This suggests that tissue-resident macrophages do not provide a substantial contribution to the myocardial inflammation in this condition.Clinical trial registration NCT02319278; Results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.